ATE293618T1 - 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel - Google Patents

4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel

Info

Publication number
ATE293618T1
ATE293618T1 AT00927184T AT00927184T ATE293618T1 AT E293618 T1 ATE293618 T1 AT E293618T1 AT 00927184 T AT00927184 T AT 00927184T AT 00927184 T AT00927184 T AT 00927184T AT E293618 T1 ATE293618 T1 AT E293618T1
Authority
AT
Austria
Prior art keywords
tumor agents
tetrahydroindazole derivatives
tetrahydroindazole
derivatives
tumor
Prior art date
Application number
AT00927184T
Other languages
English (en)
Inventor
Paolo Pevarello
Manuela Villa
Mario Varasi
Antonella Isacchi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Application granted granted Critical
Publication of ATE293618T1 publication Critical patent/ATE293618T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
AT00927184T 1999-05-12 2000-05-04 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel ATE293618T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9911053.8A GB9911053D0 (en) 1999-05-12 1999-05-12 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
PCT/EP2000/004208 WO2000069846A1 (en) 1999-05-12 2000-05-04 4,5,6,7-tetrahydroindazole derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
ATE293618T1 true ATE293618T1 (de) 2005-05-15

Family

ID=10853343

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00927184T ATE293618T1 (de) 1999-05-12 2000-05-04 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel

Country Status (26)

Country Link
US (1) US6716856B1 (de)
EP (1) EP1177185B1 (de)
JP (1) JP2002544271A (de)
KR (1) KR20010113926A (de)
CN (1) CN1350528A (de)
AR (1) AR023971A1 (de)
AT (1) ATE293618T1 (de)
AU (1) AU4564500A (de)
BR (1) BR0010476A (de)
CA (1) CA2372429A1 (de)
CZ (1) CZ20013970A3 (de)
DE (1) DE60019577T2 (de)
EA (1) EA200101194A1 (de)
ES (1) ES2239595T3 (de)
GB (1) GB9911053D0 (de)
HK (1) HK1045687A1 (de)
HU (1) HUP0201225A3 (de)
IL (1) IL146100A0 (de)
MX (1) MXPA01011441A (de)
NO (1) NO20015477L (de)
NZ (1) NZ514873A (de)
PL (1) PL351611A1 (de)
PT (1) PT1177185E (de)
SK (1) SK15712001A3 (de)
WO (1) WO2000069846A1 (de)
ZA (1) ZA200108530B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253540A1 (en) 2000-04-25 2001-11-07 Bristol-Myers Squibb Company Use of 5-thio-, sulfinyl- and sulfonylpyrazolo(3,4-b)-pyridines as cyclin dependent kinase inhibitors
CA2430151A1 (en) * 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) * 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
PT1636236E (pt) 2003-05-22 2013-12-16 Nerviano Medical Sciences Srl Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
DE602005009687D1 (de) * 2004-03-09 2008-10-23 Corcept Therapeutics Inc Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren
BRPI0607739A2 (pt) * 2005-02-25 2009-09-29 Serenex Inc derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado
WO2006133634A1 (fr) * 2005-06-14 2006-12-21 Beijing Gylongly Biodemtech Co., Ltd Dérivés tétrahydroindole et dérivés tétrahydroindazole et leur utilisation
EP1904503B1 (de) 2005-07-19 2013-11-06 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]-pyrazolverbindungen, die sich als kinaseinhibitoren eignen
MX2008003202A (es) * 2005-09-16 2008-03-25 Serenex Inc Derivados de carbazol.
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
CA2642931A1 (en) * 2006-02-27 2007-09-07 Serenex, Inc. Cyclohexylamino, benzene, pyridine, and pyridazine derivatives
WO2007099171A2 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Bicyclo-pyrazoles active as kinase inhibitors
WO2008024974A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Pyrimidine and pyrazine derivatives
WO2008024981A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Piperazine-substituted benzothiophenes for treatment of mental disorders
US20090093452A1 (en) * 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
WO2008024970A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
WO2008024978A2 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
US8293762B2 (en) 2007-02-27 2012-10-23 Nerviano Medical Sciences S.R.L. Isoquinolinopyrrolopyridinones active as kinase inhibitors
EP2003129B1 (de) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-on und 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-on-Derivate
WO2010009985A2 (en) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
WO2010088050A2 (en) 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102311389A (zh) * 2010-06-29 2012-01-11 王小龙 一种氮芳香取代吡唑衍生物、及其合成和抗癌应用
CA2812223C (en) 2010-12-17 2019-03-12 Nerviano Medical Sciences S.R.L. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
EP2661175A4 (de) 2011-01-07 2013-12-04 Corcept Therapeutics Inc Kombinationssteroid- und glucocorticoid-rezeptorantagonistentherapie
US20150141372A1 (en) * 2012-05-11 2015-05-21 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3848027T3 (pl) 2013-11-25 2023-07-24 Corcept Therapeutics Incorporated Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego
RU2019129299A (ru) 2017-03-31 2021-04-30 Корсепт Терапьютикс, Инк. Модуляторы глюкокортикоидного рецептора для лечения рака шейки матки
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
JP7218438B2 (ja) 2018-12-19 2023-02-06 コーセプト セラピューティクス， インコーポレイテッド レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
KR20210118971A (ko) 2019-02-22 2021-10-01 코어셉트 쎄라퓨틱스 인코포레이티드 헤테로아릴-케톤 융합 아자데칼린 글루코코르티코이드 수용체 조절제인 렐라코릴란트의 치료 용도
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
CN115087655A (zh) 2019-12-20 2022-09-20 辉瑞公司 苯并咪唑衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657438A (en) * 1968-09-27 1972-04-18 Ciba Geigy Corp Compositions and methods for treating inflammation
US3657270A (en) * 1970-01-16 1972-04-18 Parke Davis & Co 1-phenyl-1h-indazole-4-acetic acids
US3691180A (en) * 1970-07-31 1972-09-12 Ciba Geigy Corp Cycloalkano (c)pyrazoles
JPS60130521A (ja) 1983-12-19 1985-07-12 Morishita Seiyaku Kk 抗癌剤
JPS6299361A (ja) 1985-10-25 1987-05-08 Morishita Seiyaku Kk インデノ〔１，２−ｃ〕ピラゾ−ル誘導体
KR880009024A (ko) 1987-01-27 1988-09-13 게리 디.스트리트 기관지 확장제용 디피라졸
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CN1278725A (zh) * 1997-10-06 2001-01-03 巴斯福股份公司 茚并[1,2－c]－、萘并[1,2－c]－和苯并[6,7]芳庚并[1,2－c]吡唑类衍生物
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
GB9911053D0 (en) 1999-07-14
SK15712001A3 (sk) 2002-06-04
US6716856B1 (en) 2004-04-06
MXPA01011441A (es) 2002-10-21
HUP0201225A2 (en) 2002-08-28
WO2000069846A1 (en) 2000-11-23
DE60019577T2 (de) 2006-03-09
KR20010113926A (ko) 2001-12-28
DE60019577D1 (de) 2005-05-25
HUP0201225A3 (en) 2003-11-28
EP1177185B1 (de) 2005-04-20
HK1045687A1 (zh) 2002-12-06
EP1177185A1 (de) 2002-02-06
JP2002544271A (ja) 2002-12-24
AR023971A1 (es) 2002-09-04
NO20015477D0 (no) 2001-11-08
CZ20013970A3 (cs) 2002-04-17
PL351611A1 (en) 2003-05-05
CA2372429A1 (en) 2000-11-23
NO20015477L (no) 2002-01-11
IL146100A0 (en) 2002-07-25
NZ514873A (en) 2004-05-28
AU4564500A (en) 2000-12-05
ZA200108530B (en) 2003-02-03
EA200101194A1 (ru) 2002-06-27
ES2239595T3 (es) 2005-10-01
CN1350528A (zh) 2002-05-22
PT1177185E (pt) 2005-08-31
BR0010476A (pt) 2003-07-01

Similar Documents

Publication Publication Date Title
ATE293618T1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
TR200000520A3 (tr) 4-Fenil-piridin türevleri.
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
DE60025385D1 (de) 2,4-diaminopyrimidinderivate als immunosuppressiva
ATE293104T1 (de) Thiazolylamid-derivate
EE200100613A (et) 13-metüülerütromütsiini derivaadid
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
ATE270270T1 (de) Neuartige phenylalkyloxy-phenyl-derivate
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
NO20020565D0 (no) Interleukin-5-hemmende 6-azauracilderivater
NO20003825L (no) 1,3,4 - oxadiazolonderivater
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de) Resorcinderivate
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DE60001736T2 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
DE60000826T2 (de) 14.beta.,17-alpha-hydroxymethylandrostan derivate als androgene
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1177185

Country of ref document: EP

REN Ceased due to non-payment of the annual fee